# Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

> **NCT00467194** · PHASE1 · COMPLETED · sponsor: **National Cancer Centre, Singapore** · enrollment: 27 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00467194
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467194, "Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00467194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*